CN115151644B - 癌基因治疗药 - Google Patents

癌基因治疗药 Download PDF

Info

Publication number
CN115151644B
CN115151644B CN202080090551.5A CN202080090551A CN115151644B CN 115151644 B CN115151644 B CN 115151644B CN 202080090551 A CN202080090551 A CN 202080090551A CN 115151644 B CN115151644 B CN 115151644B
Authority
CN
China
Prior art keywords
gly
leu
ser
pro
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080090551.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN115151644A (zh
Inventor
白川利朗
国村尚人
北川孝一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kobe University NUC
Original Assignee
Kobe University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobe University NUC filed Critical Kobe University NUC
Publication of CN115151644A publication Critical patent/CN115151644A/zh
Application granted granted Critical
Publication of CN115151644B publication Critical patent/CN115151644B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080090551.5A 2019-12-27 2020-12-16 癌基因治疗药 Active CN115151644B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019-239677 2019-12-27
JP2019239677 2019-12-27
PCT/JP2020/046891 WO2021131944A1 (ja) 2019-12-27 2020-12-16 癌遺伝子治療薬

Publications (2)

Publication Number Publication Date
CN115151644A CN115151644A (zh) 2022-10-04
CN115151644B true CN115151644B (zh) 2024-06-21

Family

ID=76575495

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080090551.5A Active CN115151644B (zh) 2019-12-27 2020-12-16 癌基因治疗药

Country Status (5)

Country Link
US (1) US12459984B2 (https=)
EP (1) EP4083213A4 (https=)
JP (1) JP7737708B2 (https=)
CN (1) CN115151644B (https=)
WO (1) WO2021131944A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115151644B (zh) 2019-12-27 2024-06-21 国立大学法人神户大学 癌基因治疗药
WO2025110147A1 (ja) * 2023-11-20 2025-05-30 国立大学法人神戸大学 がんの遺伝子治療薬

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105814202A (zh) * 2013-09-30 2016-07-27 佐路闻蒂斯有限公司 Notch1特异性sirna分子

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090118175A1 (en) * 2005-05-06 2009-05-07 Macina Roberto A Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer
WO2015092024A2 (en) 2013-12-20 2015-06-25 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
US20160125127A1 (en) * 2014-10-29 2016-05-05 Council Of Scientific & Industrial Research Identification of minimal combinations of oncoproteins in notch pathway to suppress human glioblastoma
WO2016138034A1 (en) * 2015-02-24 2016-09-01 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
JP7500195B2 (ja) 2016-08-23 2024-06-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法
CN110437339B (zh) * 2018-05-04 2021-08-13 免疫靶向有限公司 一种以白介素15为活性成分的融合蛋白型药物前体
CN115151644B (zh) 2019-12-27 2024-06-21 国立大学法人神户大学 癌基因治疗药

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105814202A (zh) * 2013-09-30 2016-07-27 佐路闻蒂斯有限公司 Notch1特异性sirna分子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
付伟 ; 秦鸿雁 ; 严学倩 ; 于恒超 ; 韩骅 ; 梁英民 ; .LIM结构域蛋白FHL1C抑制Notch信号途径的转录激活研究.现代生物医学进展.2011,(04),第66-70页. *

Also Published As

Publication number Publication date
EP4083213A4 (en) 2024-01-10
CN115151644A (zh) 2022-10-04
US20230067359A1 (en) 2023-03-02
JP7737708B2 (ja) 2025-09-11
WO2021131944A1 (ja) 2021-07-01
US12459984B2 (en) 2025-11-04
WO2021131944A8 (ja) 2022-07-21
JPWO2021131944A1 (https=) 2021-07-01
EP4083213A1 (en) 2022-11-02

Similar Documents

Publication Publication Date Title
ES2962651T3 (es) Composiciones y métodos para la inhibición de antígenos específicos de linaje
CN107033248B (zh) 识别癌胚抗原的嵌合抗原受体及其应用
AU2018388079B2 (en) Immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, IL-7 and CCL19
CN116419927A (zh) 双特异性抗体car细胞免疫疗法
CN109862912A (zh) 携带双特异性T细胞衔接器（BiTE）的腺病毒
CN110248669A (zh) 工程化天然杀伤细胞及其用途
US20240424025A1 (en) Chimeric antigen receptor compositions and methods for treating muc1* diseases
CN115151644B (zh) 癌基因治疗药
US11215618B2 (en) Articles and methods directed to personalized therapy of cancer
JP2005519584A5 (https=)
EP4458956A1 (en) Anti-mesothelin nanobody chimeric antigen receptor and use thereof
CN110004167A (zh) 靶向vegfr-2和/或vegfr-3嵌合抗原受体及其应用
CN108329387B (zh) 癌症相关的肿瘤特异转录本lin28b-tst及其用途
CA3245338A1 (en) METHOD OF TREATMENT FOR PANCREATIC CANCER
Lucansky et al. DNA vaccination against bcr-abl-positive cells in mice
WO2012048667A1 (zh) 表皮生长因子受体的外显子缺失变异体
US12111319B2 (en) Articles and methods directed to personalized therapy of cancer
JP2005538697A (ja) 新規前立腺腫瘍特異的プロモーター
WO2025110147A1 (ja) がんの遺伝子治療薬
HK40088596A (zh) 细胞分类器回路及其使用方法
CN101330925A (zh) 用d114拮抗剂抑制肿瘤生长的治疗方法
KR101421792B1 (ko) Ｐａｐ의 세포외 도메인에 선택적으로 결합하는 ｒｎａ 앱타머
CN115702247A (zh) 细胞分类器回路及其使用方法
TW200902978A (en) Methods for inhibition of proliferative disease, including hepatocellular carcinoma

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant